Oncodex is an injection that contains the generic medicine ondansetron, given as 8 mg/4 ml. It belongs to a group of medicines called anti-emetics, which are used to help prevent or treat nausea and vomiting in certain situations. It is made by Jayson Pharmaceuticals Ltd.
There are 74 brands of Ondansetron listed in Bangladesh. 26 of them have a lower unit price than Oncodex. The lowest listed price is Periset 16 mg Suppository at ৳ 1 per unit.
What is Oncodex 8 mg/4 ml Injection?
Oncodex is an injection containing ondansetron, an anti-emetic medicine. It is available as an 8 mg/4 ml strength in a 4 ml ampoule, supplied in packs of 5. Anti-emetics are medicines used to help manage nausea and vomiting. Ondansetron works by blocking a substance in the body called serotonin at certain receptor sites, which are involved in the vomiting reflex. Oncodex is given by a healthcare professional. Whether it is suitable for a particular person depends on their condition and medical history, so the doctor or pharmacist should be asked if you have questions.
Uses of Oncodex
Oncodex is used to help prevent nausea and vomiting linked to certain cancer chemotherapy treatments. It is also used to prevent and treat nausea and vomiting that can happen after an operation, and to help prevent nausea and vomiting caused by radiotherapy. It is given by a healthcare professional in a clinic or hospital setting. Ask the doctor if you are unsure why this medicine has been prescribed for you or someone in your care.
How to use Oncodex
Oncodex is an injection, so it is given by a doctor, nurse or other trained healthcare professional. You should not try to inject it yourself. The doctor decides the dose and how long the course should last, based on the person's condition and needs. Tell the healthcare team about any other medicines being taken, and ask them any questions you have about how it will be given.
Side effects of Oncodex
Some people may notice side effects after receiving Oncodex. Commonly reported ones include headache, constipation and diarrhoea, and these are often mild or moderate. Rash has been reported in some patients receiving ondansetron for chemotherapy-related nausea and vomiting. Other reported effects include a feeling of flushing or warmth, hiccups and changes in liver enzyme tests. Rare reports include allergic-type reactions, breathing problems, fast heartbeat, chest pain and low potassium. Tell the doctor or nurse if you feel unwell after the injection.
Safety and precautions
Oncodex should not be used by anyone who has had an allergic reaction to ondansetron or any of its ingredients. It should not be given together with apomorphine. Tell the doctor about allergies to other similar medicines, and about any stomach or bowel problems, especially after abdominal surgery, because this medicine can hide signs of a developing problem. There are no adequate, well-controlled studies in pregnant women, so if you are pregnant, planning a pregnancy or breastfeeding, ask the doctor before it is given. The doctor will decide whether it is suitable for you.
Frequently asked questions
What does the dosage form and strength of Oncodex mean?
Oncodex is an injection, which means it is given by a healthcare professional rather than taken by mouth. The strength is 8 mg/4 ml, meaning each 4 ml ampoule contains 8 mg of ondansetron. It is supplied in a pack of 5 ampoules. Ask the doctor or pharmacist if you need more detail.
What is Oncodex used for and what kind of medicine is it?
Oncodex contains ondansetron, which is an anti-emetic medicine. It is used to help prevent nausea and vomiting linked to certain chemotherapy, to prevent and treat nausea and vomiting after an operation, and to help prevent nausea and vomiting caused by radiotherapy. Ask the doctor if you are unsure why it has been prescribed.
How should Oncodex be taken?
Oncodex is an injection and is given by a doctor, nurse or other trained healthcare professional. It is not something you give yourself. The doctor decides the dose and the length of the course based on the person's condition. Ask the healthcare team if you have questions about how it will be given.
Ondansetron is a serotonin subtype 3 (5-HT3) receptor antagonist indicated:
Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
Prevention and treatment of post-operative nausea and vomiting.
Prevention of radiotherapy-induced nausea and vomiting.
Pharmacology
Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system. The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.
Dosage & Administration
Chemotherapy-Induced Nausea and Vomiting- Adults, Pediatric patients (6 months to 18 years):
8 mg tablet/orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Radiotherapy-Induced Nausea and Vomiting- Adults:
8 mg tablet/orodispersible tablet: Initial Dose: 8 mg orally 1 to 2 hours before radiotherapy. Post Radiotherapy: 8 mg orally every 8 hours for up to 5 days after a course of treatment.
4 mg orodispersible tablet: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose.
Injection: Three 0.15 mg/kg doses, up to a maximum of 16 mg per dose, infused intravenously over 15 minutes.
Postoperative Nausea and Vomiting- Adults:
8 mg tablet/orodispersible tablet: 16 mg given as two 8 mg tablets
Chemotherapy-induced Nausea and Vomiting- Adults/Geriatric/Child of 12 years or over:
Highly emetogenic cancer chemotherapy: 30 ml (24 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy.
Moderate emetogenic cancer chemotherapy: 10 ml (8 mg) Ondansetron Oral Solution administered 30 minutes before start of emetogenic chemotherapy. A further 10 ml dose should be administered after 8 hours of the first dose. One 10 ml dose should be administered twice a day (every 12 hours) for 1-2 days after completion of chemotherapy.
Pediatric (4-11 years): 5 ml (4 mg) Ondansetron Oral Solution should be taken 30 minutes before the start of chemotherapy. The other 2 doses should be taken 4 and 8 hours after the first dose. Then 5 ml oral solution should be administered 3 times a day (every 8 hours) for 1-2 days after completion of chemotherapy.
Oral solution:
Radiotherapy induced Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
The recommended oral dosage: 10 ml (8 mg) Ondansetron Oral Solution 3 times daily.
For total body irradiation: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before each fraction of radiotherapy administered each day.
For single high-dose fraction radiotherapy to the abdomen: one 10 ml Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for 1 to 2 days after completion of radiotherapy.
For daily fractionated radiotherapy to the abdomen: 10 ml (8-mg) Ondansetron Oral Solution should be administered 1 to 2 hours before radiotherapy, with subsequent doses every 8 hours after the first dose for each day radiotherapy is given.
Postoperative Nausea and Vomiting (Adults/Geriatric/Child of 12 years or over):
20 ml (16 mg) Ondansetron Oral Solution 1 hour before induction of anesthesia
Oral Soluble Film:
Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:
Adult oral dose: 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy.
Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:
Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.
Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.
Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day.
Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia.
Interaction
Ondansetron does not itself appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver. Because Ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance and hence, the half-life of Ondansetron. On the basis of available data, no dosage adjustment of Ondasetron is recommended for patients on these drugs.
Contraindications
Contraindicated in patients known to have hypersensitivity to the drug or any of its components. Concomitant use of apomorphine.
Side Effects
Frequently reported adverse events were headache, constipation and diarrhea, but the majority have been mild or moderate in nature. In chemotherapy-induced nausea and vomiting, rash has occurred in approximately 1% of patients receiving Ondansetron. There also have been reports to a sensation of flushing or warmth, hiccups and liver enzyme abnormalities. Rare cases of anaphylaxis, brochospasm, tachycardia, angina (chest pain), hypokalemia, shortness of breath have also been reported, except for bronchospasm and anaphylaxis, the relationship to Ondansetron is unclear. There have been no evidence to extrapyramidal reactions, in rare case oculogyric crisis appearing alone, as well as with other dystonic reactions without definitive clinical evidence. In case of PONV, with the exception of headache, rates of these events were not significantly different in the Ondansetron and placebo groups.
Pregnancy & Lactation
Carcinogenic effects were not seen in 2-year studies in rats and mice with oral Ondansetron doses up to 10 and 30 mg/kg per day, respectively. Ondansetron was not mutagenic in standard tests for mutagenicity. Oral administration of Ondansetron up to 15 mg/kg per day did not affect fertility or general reproduction performance of male and female rats.
Reproduction studies have been performed in pregnant rats and rabbits at daily oral doses up to 15 and 30 mg/kg per day, respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. There are, however, no adequate and well-controlled studies in pregnant women. Ondansetron is excreted in the breast milk of rats. So caution should be exercised when Ondansetron is administered to a nursing women.
Precautions & Warnings
Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists. Ondansetron is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction. The use of Ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and/or gastric distension.
Storage Conditions
Store at temperature not exceeding 30ºC in a dry place. Protect from light and moisture.
Alternative brands of Ondansetron
Other brands with the same generic name, cheapest first.